<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To assess the efficacy and tolerability of alogliptin plus <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> for initial combination therapy in drug-naïve type 2 diabetic patients </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: This 26-week, double-blind, parallel-group study randomized 655 patients with inadequately controlled type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> to four arms: 25 mg alogliptin (A25) q.d. monotherapy, 30 mg <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (P30) q.d. monotherapy, or 12.5 (A12.5) or 25 mg alogliptin q.d. plus <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (P30) q.d. combination therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Primary efficacy was A1C change from baseline with the high-dose combination (A25+P30) versus each monotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Combination therapy with A25+P30 resulted in greater reductions in A1C (-1.7±0.1% from an 8.8% mean baseline) vs. A25 (-1.0±0.1%, P&lt;0.001) or P30 (-1.2±0.1%, P&lt;0.001) and in fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (-2.8±0.2 mmol/l) vs. A25 (-1.4±0.2 mmol/l, P&lt;0.001) or P30 (-2.1±0.2 mmol/l, P=0.006) </plain></SENT>
<SENT sid="4" pm="."><plain>The A25+P30 safety profile was consistent with those of its component monotherapies </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: Alogliptin plus <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> combination treatment appears to be an efficacious initial therapeutic option for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>